Welcome to Pfizer Scientific Technical Limited Company
Pfizer Saudi... Committed to YouCoinciding with the 175th anniversary of Pfizer, with more than a six-decade presence in the Kingdom, Pfizer Saudi launched a corporate awareness campaign “Pfizer Saudi... Committed to You.” With this campaign, Pfizer Saudi reinforces its commitment to the health of the people in the Kingdom, and to contributing to developing and building a future where science will winFind out moreFOREWORD BY THE DIRECTOR - GENERALPfizer is a Research Based Global Biopharmaceutical Company that Engaged in the Discovery, Development & Manufacturing of Healthcare ProductsPfizer is a research based global biopharmaceutical company that engaged in the discovery, development & manufacturing of healthcare products that includes medicines and vaccines to improve patient’s lives. It has been operating in Saudi Arabia since early 1960s. And it has a portfolio in different therapeutic areas include internal medicines, vaccines, oncology, inflammation & Immunolog...Find out more
FOREWORD BY THE DIRECTOR - GENERALPfizer in Saudi Arabia Signed a Memorandum of Understanding with the Saudi Arabian General Investment AuthorityIn October 2011, Pfizer in Saudi Arabia signed a memorandum of understanding with the Saudi Arabian General Investment Authority (SAGIA) to set up its first ever manufacturing plant throughout the GCC in King Abdullah Economic City in Saudi Arabia & kicked off the construction of its new manufacturing plant in February 2013. The full manufacturing & packaging was completed by 2017.Find out more
FOREWORD BY THE DIRECTOR - GENERALMaking Pfizer the First Pharmaceutical Multinational Companies was Awarded such a LicenseOn June 22, 2016 SAGIA issued a “trading license” to Pfizer, making Pfizer the first pharmaceutical multinational companies was awarded such a license. The new license, which is effective immediately, gives Pfizer “100 percent foreign ownership” of its legal entity in Saudi Arabia with the ability to import, export, and trade in wholesale and retail products, equipment, and instruments. ...Find out more
FOREWORD BY THE DIRECTOR - GENERALThe Total Number of 4.4 Million Patients in Saudi Arabia Benefited from Pfizer’s Innovative and Diversified Therapies During 2019.The total number of 4.4 Million patients in Saudi Arabia benefited from Pfizer’s innovative and diversified therapies during 2019. Additionally, Pfizer Saudi Vaccines had helped in protection of more than 5 million children in Saudi Arabia from serious infections of invasive and mucosal pneumococcal disease during the last 12 years, and continue to provide innovation in the immunization ...Find out more